Nuvation Bio, Inc. Class A (NUVB)

Nuvation Bio's stock price was $4.79 as of May 8, 2026, a 129.19% increase from May 9, 2025, but has decreased by 46.7% since the start of 2026. Positive events include FDA acceptance of a supplemental New Drug Application for IBTROZI, its inclusion in NCCN guidelines, strong first-quarter 2026 financial results, and presentation of updated clinical data at AACR 2026. The EMA validated the Marketing Authorisation Application (MAA) for taletrectinib. Negative events include announcements of shareholder investigations by law firms.

There is no explicit information indicating demand seasonality for Nuvation Bio's products. Demand is primarily driven by factors such as the prevalence of targeted cancers, the efficacy and safety profile of its therapies, regulatory approvals, and physician adoption. Consistent new patient starts for IBTROZI suggest a steady demand rather than seasonal fluctuations.

Nuvation Bio, Inc. is a global biopharmaceutical company focused on developing novel oncology therapeutics. The company's portfolio includes taletrectinib (IBTROZI®), safusidenib, and an innovative drug-drug conjugate program. Nuvation Bio combines internal R&D with in-licensed assets and partnerships, and began commercializing IBTROZI in the U.S. in June 2025.

Nuvation Bio is dual-headquartered in New York and San Francisco, with offices in Boston and a presence in Asia. The company develops and commercializes targeted cancer therapies and conducts multinational clinical programs. It has partnerships in China and Japan for market execution and an exclusive licensing agreement with Eisai for taletrectinib in Europe and selected countries. The majority of its revenue comes from Japan.

Nuvation Bio's brand reputation is largely positive due to clinical and commercial milestones, including becoming a commercial-stage company in 2025. The FDA's acceptance of a supplemental New Drug Application for IBTROZI and its inclusion in the NCCN Guidelines for CNS cancers are strong indicators of positive scientific and medical recognition. The presentation of updated clinical data at AACR 2026, highlighting the impressive durability of response for IBTROZI, further enhances its reputation within the oncology community. However, shareholder investigations could potentially impact brand reputation.

Nuvation Bio's stock ownership includes institutional investors (16.40% to 61.67%), insiders (24.91% to 30.11%), and public/individual investors (approximately 49.02%). Major institutional owners include Fmr Llc, Decheng Capital LLC, BlackRock, Inc., Vanguard Group Inc, Omega Fund Management, LLC, Laurion Capital Management LP, State Street Corp, Geode Capital Management, Llc, and Tang Capital Management Llc. David Hung, the CEO, owns the most shares among individuals. Insiders have sold more stock than they have bought in the past three months.